Pharma Index Down 2%, but Selloff could be an ‘Exaggeration’

Nifty’s Pharma index saw a decline after US President Trump announced a 100 percent tariff on branded drugs from October 1. Analysts noted India’s limited exposure to patented drugs in the US market. Most Indian firms focus on generic medicines, which are not affected by the new tariff. Major Indian players also operate manufacturing facilities within the United States.

More To Explore

Tata Capital invests in Vodafone Idea bond issue

Non-banking financial companies (NBFCs) like Tata Capital, JM Financial Credit Solutions, Aditya Birla Capital, and Hero Fincorp have collectively invested around ₹1,300 crore in Vodafone

December 22, 2025

Advertiser Disclosure

Great-investor.com helps users across the globe to find out The latest news, Guides, and Info about finance and investments. Furthermore, our content and research teams do not participate in any advertising planning nor are they permitted access to advertising campaign data.

Disclaimer

It is our organization’s primary mission to provide reviews, commentary, and analysis that are unbiased and objective. While great-investor.com has some data verified by industry participants, it can vary from time to time. Operating as an online business, this site may be compensated through third party advertisers. Our receipt of such compensation shall not be construed as an endorsement or recommendation by great-investor.com, nor shall it bias our reviews, analysis, and opinions. Please see our General Disclaimers for more information.

The information on this website does not constitute investment advice or a recommendation or a solicitation to engage in any investment activity. This website and its content are not intended for residents of the UAE, US, Canada, Australia, UK, Russia, North Korea, China, Japan, Hong Kong, Singapore and Iran.

Top10 International FZ LLE | 17th Floor, Creative Tower | 4422 | Fujairah | TRN: 100608946800003